New Era in Vitiligo and Atopic Dermatitis Treatment with Opzelura
DOI:
https://doi.org/10.5281/zenodo.15775399Keywords:
Opzelura, Vitiligo, RuxolitinibAbstract
In recent years, topical Janus kinase (JAK) inhibitors have emerged as promising novel agents for the treatment of inflammatory skin diseases such as vitiligo and atopic dermatitis. The FDA-approved Opzelura® (ruxolitinib 1.5% cream) has demonstrated significant efficacy and safety in clinical trials. Phase 3 studies in vitiligo patients showed marked repigmentation, while atopic dermatitis trials reported substantial symptom reduction and improved quality of life. These recent findings from Europe and the United States reinforce the therapeutic role of ruxolitinib cream in dermatology. However, the lack of regulatory approval in Turkey restricts patient access to this innovative treatment. This letter highlights the urgent need for Opzelura’s approval in Turkey, emphasizing its potential as a vital option for treatment-resistant patients and its contribution to advancing dermatological practice
References
Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: pathogenesis and new and emerging treatments. Int J Mol Sci. 2023;24(24):17306.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-55.
Kang C. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. Drugs. 2024;84(5):579-86.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-72.
Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023;37(11):2222-30.
Hwang JR, Driscoll MS. Review of ruxolitinib for treatment of non-segmental vitiligo. Ann Pharmacother. 2023;57(8):948-55.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MEHES JOURNAL

This work is licensed under a Creative Commons Attribution 4.0 International License.